AFM
IRD

Anson Funds Management’s Opus Genetics IRD Stock Holding History

Anson Funds Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,339
Closed -$149K – 219
2023
Q4 		$149K Buy
+49,339
New +$146K 0.02% 150
2019
Q1 		– Sell
-12,648
Closed -$565K – 53
2018
Q4 		$565K Buy
+12,648
New +$739K 0.33% 17
2017
Q3 		– Sell
-10,901
Closed -$1.5M – 63
2017
Q2 		$1.5M Buy
+10,901
New +$2.12M 0.47% 27
2017
Q1 		– Sell
-11,270
Closed -$768K – 83
2016
Q4 		$768K Sell
11,270
-7,834
-41% -$638K 0.24% 38
2016
Q3 		$1.93M Buy
+19,104
New +$2.31M 0.41% 29

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Anson Funds Management's IRD Position: Q1 2024 in Review

Anson Funds Management sold out of Opus Genetics (IRD) in Q1 2024, closing a stake of 49,339 shares — an estimated $149K sold.

Anson Funds Management first reported a position in IRD in Q3 2016 and held it in 5 quarters. The position peaked at $1.93M in Q3 2016. 49 funds tracked by Wall St. Rank hold IRD as of Q1 2024.

  • Anson Funds Management reported no remaining Opus Genetics position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 49,339 Opus Genetics shares in Q1 2024, an estimated $149K.
  • Anson Funds Management first reported a position in Opus Genetics in Q3 2016 and held it in 5 quarters.
  • Anson Funds Management's Opus Genetics position peaked at $1.93M in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.